الفهرس | Only 14 pages are availabe for public view |
Abstract Ketorolac is a potent non-steroidal analgesic drug, frequently used for treatment of rheumatoid arthritis, osteoarthritis, a variety of other acute and chronic musculoskeletal disorders and mild to moderate pain. The drug acts as antiinflammatory by inhibiting prostaglandin synthetase cyclooxygenase. It is 36 times more potent than phenyl butazone, and twice as that of indomethacin. The oral administration of ketorolac is associated with high risk of adverse effect such as irritation, ulceration, bleeding of gastrointestinal tract, edema as well as peptic ulceration. These attributes make ketorolac a good candidate for controlled release dosage form, so as to ensure slow release of the drug eliminating the disturbance of the gastrointestinal tract. Co-administration of combination of paracetamol with non-steroidal antiinflammatory drugs showed synergistic effects leading to validation of clinical use of this combination in the treatment of majority of pain conditions. Our research underlines the importance of minimizing the ulcerogenic effect of ketorolac by preventing its direct contact with the GIT by coating with protective polymers. |